Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-Year follow-up

Gynecologic Oncology

Volumn 83, Issue 3, 2001, Pages 549-554

  Hasenburg, A ^a,b   Tong, X W ^a,b   Fischer, Ph D , D C ^a   Rojas Martinez, A ^b   Nyberg Hoffman, C ^b   Kaplan, A L ^b   Kaufman, R H ^b   Ramzy, I ^b   Aguilar Cordova, E ^b   Kieback, D G ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Intraperitoneal therapy; Recurrent ovarian cancer; Survival; Thymidine kinase gene therapy

Indexed keywords

ACICLOVIR; THYMIDINE KINASE; TOPOTECAN;

ADENOVIRUS; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; GENE THERAPY; HUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SECOND LOOK SURGERY; TREATMENT OUTCOME;

EID: 0035205990     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6442     Document Type: Article

References (44)

1. Cancer statistics, 2000
2. Descriptive epidemiology of ovarian cancer in Europe
3. Epidemiological and molecular aspects of ovarian cancer risk
4. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
5. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy
6. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings
7. Lack of improvement in survival in patients with relapsed or refractory epithelial ovarian cancer 1980-1997
8. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer
9. Phase II study of intravenous topotecan as a 5-day infusion for retractory epithelial ovarian carcinoma
10. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
11. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy
12. Curability of tumors bearing herpes simplex virus thymidine kinase gene
13. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy
14. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
15. The "bystander effect:" Tumor regression when a fraction of the tumor mass is genetically modified
16. 'Bystander killing' induces apoptosis and is inhibited by forskolin
17. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro
18. Replicating viruses as selective cancer therapeutics
19. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
20. Adenovirusmediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir
21. Immune system in suicide-gene therapy
22. Gene therapy and ovarian cancer: A review
23. Prodrug-activating systems in suicide gene therapy
24. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration
25. Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy
26. Improvement of gene therapy for ovarian cancer by using acyclovir: In vitro study of adenovirus mediated thymidine kinase gene therapy followed by exposure to acyclovir vs conventional ganciclovir
27. Adenovirus mediated tymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to selected chemotherapeutic agents
28. "Recurrence within 6 months of platinum therapy:" An adequate definition of "platinum-refractory" ovarian cancer
29. 2nd-line chemotherapie nach platin-oder platin-paclitaxel-haltiger primärtherapie beim ovarialkarzinom: Eine systematische übersicht der publizierten daten bis 1998
30. Chemotherapy in recurrent epithelial ovarian cancer (EOC): An analysis of prognostic factors
31. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats
32. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo
33. Safety of in vivo adenovirus-mediated thymidine kinase treatment of oral cancer
34. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model
35. Adenovirus-mediated gene therapy of experimental gliomas
36. The treatment of ovarian cancer with a gene modified cancer vaccine: A phase I study
37. Das fortgeschrittenen ovarialkarzinom
38. Aktuelle aspekte des ovarialkarzinomsa
39. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
40. Operative therapie progredienter oder rezidivierender maligner ovarialtumoren
41. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer
42. Interim analysis of a phase III randomized trial of doxil/caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer
43. Phase I/II gene therapy in recurrent ovarian cancer with intraperitoneal recombinant adenoviral human p53